Newsroom
Supply notes, process and method updates, and perspectives from the people doing the work.
Sports Medicine maps the unapproved peptide market; separately, one of the peptides it covers now has an approved reference product.
The amylin and GLP-1 fixed combination was superior to semaglutide alone over sixty-eight weeks in 2,713 participants across thirty countries.
A controlled animal study sets the two peptides, and their combination, against surgical repair alone.
The phase 2 EMBRAZE trial in Nature Medicine puts a myostatin-targeting antibody in the same protocol as an incretin agonist.
The agency’s standing alert on unapproved GLP-1 products now names both molecules directly, and describes warnings issued to the distributors selling them.
TRANSCEND-T2D-1, published in The Lancet, ran the triple agonist as a monotherapy over forty weeks in 537 participants.